


Olverembatinib dimesylate

Cat. No.:	HY-15666A
CAS No.:	1421783-64-3
Molecular Formula:	C ₃₁ H ₃₅ F ₃ N ₆ O ₇ S ₂
Molecular Weight:	724.77
Target:	Bcr-Abl
Pathway:	Protein Tyrosine Kinase/RTK
Storage:	4°C, sealed storage, away from moisture and light * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 125 mg/mL (172.47 mM; Need ultrasonic)
 H₂O : ≥ 50 mg/mL (68.99 mM)
 * "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	1.3797 mL	6.8987 mL	13.7975 mL
	5 mM	0.2759 mL	1.3797 mL	2.7595 mL
	10 mM	0.1380 mL	0.6899 mL	1.3797 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 2.08 mg/mL (2.87 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.08 mg/mL (2.87 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.08 mg/mL (2.87 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Olverembatinib (GZD824) dimesylate is a potent and orally active pan-Bcr-Abl inhibitor. Olverembatinib dimesylate potently inhibits a broad spectrum of Bcr-Abl mutants. Olverembatinib dimesylate strongly inhibits native Bcr-Abl and Bcr-Abl^{T315I} with IC₅₀s of 0.34 nM and 0.68 nM, respectively. Olverembatinib dimesylate has antitumor activity^[1]. Olverembatinib (dimesylate) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAC) with molecules containing Azide groups.

IC₅₀ & Target	IC50: 0.68 nM (Bcr-Abl ^{T315I}), 0.27 nM (Bcr-Abl ^{E255K}), 0.71 nM (Bcr-Abl ^{G250E}), 0.15 nM (Bcr-Abl ^{Q252H}), 0.35 nM (Bcr-Abl ^{H396P}), 0.29 nM (Bcr-Abl ^{M351T}), 0.35 nM (Bcr-Abl ^{Y253F}), Bcr-Abl ^{F317L} [1]																
In Vitro	<p>Olverembatinib dimesylate shows antiproliferative activity in stably transformed Ba/F3 cells whose growth was driven by native Bcr-Abl or Bcr-Abl mutants^[1].</p> <p>Olverembatinib dimesylate selectively and potently inhibits the proliferation of Bcr-Abl-positive leukemia cells^[1].</p> <p>Olverembatinib dimesylate inhibits Bcr-Abl signaling in K562 (1-20 nM; 4.0 hours) and Ba/F3 stable cell lines expressing native Bcr-Abl (0.1-100 nM; 4.0 hours) or Bcr-Abl^{T315I}(0.1-100 nM; 4.0 hours)^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Western Blot Analysis^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>K562 cells</td> </tr> <tr> <td>Concentration:</td> <td>1 nM, 2 nM, 5 nM, 10 nM, 20nM</td> </tr> <tr> <td>Incubation Time:</td> <td>4.0 hours</td> </tr> <tr> <td>Result:</td> <td>Inhibited Bcr-Abl signaling in K562 cell lines.</td> </tr> </table>	Cell Line:	K562 cells	Concentration:	1 nM, 2 nM, 5 nM, 10 nM, 20nM	Incubation Time:	4.0 hours	Result:	Inhibited Bcr-Abl signaling in K562 cell lines.								
Cell Line:	K562 cells																
Concentration:	1 nM, 2 nM, 5 nM, 10 nM, 20nM																
Incubation Time:	4.0 hours																
Result:	Inhibited Bcr-Abl signaling in K562 cell lines.																
In Vivo	<p>Olverembatinib dimesylate suppresses tumor growth in mice bearing allografted Ba/F3 cells expressing Bcr-Abl^{WT}^[1].</p> <p>Olverembatinib dimesylate (1-20 mg/kg; i.g.; daily; for 10 days) significantly increases the median survival of the mice bearing allografted Ba/F3 cells expressing Bcr-Abl^{T315I}^[1].</p> <p>Olverembatinib dimesylate exhibits a good oral bioavailability (rat 48.7%) and C_{max} (rat 390.5 µg/L) following oral administration (rat; 25 mg/kg)^[1].</p> <p>Olverembatinib dimesylate exhibits terminal elimination half-lives (rat 5.6 h) due to high plasma clearance (rat 1.7 L/h/kg) following intravenous administration (rat 5 mg/kg)^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>SCID nude mice, bearing allografted Ba/F3 cells expressing Bcr-Abl^{T315I}^[1]</td> </tr> <tr> <td>Dosage:</td> <td>1 mg/kg, 2 mg/kg, 5.0 mg/kg, 10 mg/kg, 20 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Oral gavage, daily, for 10 days</td> </tr> <tr> <td>Result:</td> <td>Efficiently prolonged animal survival in an allograft leukemia tumor model.</td> </tr> </table> <table border="1"> <tr> <td>Animal Model:</td> <td>Rats^[1]</td> </tr> <tr> <td>Dosage:</td> <td>5 mg/kg for i.v.; 25 mg/kg for oral (Pharmacokinetic Analysis)</td> </tr> <tr> <td>Administration:</td> <td>Intravenous injection and oral administration</td> </tr> <tr> <td>Result:</td> <td>Oral bioavailability (48.7%), C_{max} (390.5 µg/L), T_{1/2} (5.6 h).</td> </tr> </table>	Animal Model:	SCID nude mice, bearing allografted Ba/F3 cells expressing Bcr-Abl ^{T315I} ^[1]	Dosage:	1 mg/kg, 2 mg/kg, 5.0 mg/kg, 10 mg/kg, 20 mg/kg	Administration:	Oral gavage, daily, for 10 days	Result:	Efficiently prolonged animal survival in an allograft leukemia tumor model.	Animal Model:	Rats ^[1]	Dosage:	5 mg/kg for i.v.; 25 mg/kg for oral (Pharmacokinetic Analysis)	Administration:	Intravenous injection and oral administration	Result:	Oral bioavailability (48.7%), C _{max} (390.5 µg/L), T _{1/2} (5.6 h).
Animal Model:	SCID nude mice, bearing allografted Ba/F3 cells expressing Bcr-Abl ^{T315I} ^[1]																
Dosage:	1 mg/kg, 2 mg/kg, 5.0 mg/kg, 10 mg/kg, 20 mg/kg																
Administration:	Oral gavage, daily, for 10 days																
Result:	Efficiently prolonged animal survival in an allograft leukemia tumor model.																
Animal Model:	Rats ^[1]																
Dosage:	5 mg/kg for i.v.; 25 mg/kg for oral (Pharmacokinetic Analysis)																
Administration:	Intravenous injection and oral administration																
Result:	Oral bioavailability (48.7%), C _{max} (390.5 µg/L), T _{1/2} (5.6 h).																

CUSTOMER VALIDATION

- Research Square Print. 2023 Mar 23.
- Research Square Preprint. 2021 Oct.
- Biochim Biophys Acta. 2018 May 25;1865(9):1173-1186.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Ren X, Pan X, Zhang Z, Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib. J Med Chem. 2013 Feb 14;56(3):879-94.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA